Humacyte, Inc. - Common Stock · Transaction May 3, 2024 · Filed Aug 5, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · HUMA
+3.62% · +$0.0200 · Vol 5.4M
Market closed · last close 4:00 PM ET · price as of 19:53:12 ET
Humacyte Inc
Biotechnology
$0.5211
Follow $HUMA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $HUMA by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredSat Oct 3 · market closed · Markets closed · resumes Mon 9:30 ET · HUMA
MethodologyHUMA
Humacyte Inc
Sat Oct 3 · market closed · Markets closed · resumes Mon 9:30 ET
Lower range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
40/ 100
Veridion Score
Lower range · LOW confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6 of 6 factors measured · Sat Oct 3 · market closed · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is HUMA moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Humacyte Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2021
Employees
184
Country
US
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$0.5061
Day high
$0.5343
Day low
$0.5032
Previous close
$0.5029
52W high
$2.48
-78.99% from high
52W low
$0.5029
1% of range
Market cap
$144.9M
EPS
$-0.6000
Beta
1.82
Shares out
277.8M
Volume
5.4M
1.13× rel vol
Avg volume
4.8M
VWAP
$0.5240
Price history computed in-house
1W
-6.50%
1M
-12.57%
3M
-26.61%
1Y
-75.19%
YTD
-45.75%
SMA 50 $0.6182 · below
SMA 200 $0.8729 · below
52W position 1%
HUMA overview
Related filings and maps
Public disclosures
Congress activity in HUMA
Official filing ↗
Humacyte, Inc. - Common Stock · Transaction May 3, 2024 · Filed Aug 5, 2026 · $15,001 to $50,000
Humacyte, Inc. - Common Stock · Transaction Apr 30, 2024 · Filed May 15, 2024 · $50,001 to $100,000
Humacyte Inc · Transaction Mar 21, 2024 · Filed Aug 5, 2026 · $1,001 to $15,000
Humacyte, Inc. - Common Stock · Transaction Mar 21, 2024 · Filed Aug 5, 2026 · $15,001 to $50,000
Federal contracts
HUMA contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for HUMA in this window.
Lobbying spend
HUMA lobbying filings, year to date.
Registered lobbying filings matched to Humacyte Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for HUMA in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for HUMA.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.